Contrary to common belief, HER2 can be expressed or amplified in prostate cancer, particularly in subtypes with neuroendocrine features. This creates a rare but actionable target, with reported complete responses to HER2-directed therapies like TDXD, highlighting the need for broader genomic testing.
The investigational drug OP, a CYP11A1 inhibitor, works far upstream of abiraterone to block the creation of all adrenal steroids. This is effective against cancers with mutated androgen receptors (AR) that have become "promiscuous" and can be activated by non-androgen steroids like glucocorticoids.
Instead of administering all six planned doses of PSMA Lutetium upfront in the hormone-sensitive setting, a novel "sandwich" strategy is being considered. This involves giving a few doses, re-imaging, and reserving subsequent doses for later, potentially optimizing efficacy and managing long-term toxicity.
The EMBARK study demonstrates that an intermittent approach to androgen deprivation therapy (ADT), especially with combination ADT and enzalutamide, can provide patients with low-volume metastatic disease a median of 1.5 years off therapy, improving quality of life without compromising outcomes.
The Tolmimidostat/Luxta-degalutamide combination attacks prostate cancer on two fronts. Luxta-degalutamide is an AR degrader, while Tolmimidostat, an EZH1/2 inhibitor, has anti-AR properties and also regulates lineage plasticity, potentially preventing the cancer's shift to a more aggressive neuroendocrine state.
New guidelines from an international working group are replacing patient-insensitive terms like "castration-resistant" with "Androgen Pathway Modulator (APM) resistant/naive." This modernizes language to encompass a broader range of therapies and improve patient communication, while also incorporating sensitive imaging like PSMA PET.
The future of advanced prostate cancer treatment is shifting towards therapies that target cell surface markers. This new era will be defined by a growing arsenal of radioligands, T-cell engaging bispecific antibodies (BiTEs), and antibody-drug conjugates (ADCs) aimed at targets like PSMA, B7-H3, and HK2.
The oral GnRH antagonist Relagolix allows for much quicker testosterone recovery (1-2 months vs. 3-6 for leuprolide). While beneficial in curative-intent settings, this rapid recovery is a double-edged sword that could shorten the "off-therapy" period during intermittent treatment for metastatic disease.
Compared to beta emitters like Lutetium-177, alpha emitters (e.g., Actinium-225) deliver more potent, shorter-range energy. This is beneficial for killing tumor cells but increases the risk of severe localized toxicity in off-target tissues like salivary glands, while potentially reducing marrow suppression.